OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3652-3665
Closed Access | Times Cited: 13
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 31, pp. 3652-3665
Closed Access | Times Cited: 13
Showing 13 citing articles:
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study
O. Martínez-Sáez, Marta Tapia, Mercedes Marín‐Aguilera, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 8, pp. 100123-100123
Closed Access | Times Cited: 2
O. Martínez-Sáez, Marta Tapia, Mercedes Marín‐Aguilera, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 8, pp. 100123-100123
Closed Access | Times Cited: 2
Advances in medical treatment of breast cancer in 2022
Jingtong Zhai, Yun Wu, Fei Ma, et al.
Cancer Innovation (2023) Vol. 2, Iss. 1, pp. 1-17
Open Access | Times Cited: 28
Jingtong Zhai, Yun Wu, Fei Ma, et al.
Cancer Innovation (2023) Vol. 2, Iss. 1, pp. 1-17
Open Access | Times Cited: 28
Treatment of Early Breast Cancer
Michael Untch, Maggie Banys‐Paluchowski, Sara Y. Brucker, et al.
Geburtshilfe und Frauenheilkunde (2023) Vol. 83, Iss. 09, pp. 1102-1116
Open Access | Times Cited: 23
Michael Untch, Maggie Banys‐Paluchowski, Sara Y. Brucker, et al.
Geburtshilfe und Frauenheilkunde (2023) Vol. 83, Iss. 09, pp. 1102-1116
Open Access | Times Cited: 23
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Adrienne G. Waks, Olga Martínez‐Sáez, Paolo Tarantino, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 6
Adrienne G. Waks, Olga Martínez‐Sáez, Paolo Tarantino, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 6
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers
Filipa Lynce, O. Martínez-Sáez, Benjamín Walbaum, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104100-104100
Closed Access
Filipa Lynce, O. Martínez-Sáez, Benjamín Walbaum, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104100-104100
Closed Access
The necessity of adjuvant chemotherapy in young patients with T1N0M0 breast cancer: a population-based study
Sheng Chen, Shujie Chen, Wei Cao, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Sheng Chen, Shujie Chen, Wei Cao, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
Ilana Schlam, Sherene Loi, Roberto Salgado, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104120-104120
Closed Access
Ilana Schlam, Sherene Loi, Roberto Salgado, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104120-104120
Closed Access
HER2DX genomic test in early-stage HER2-positive breast cancer
Sara M. Tolaney, Nadine Tung, Antonio C. Wolff, et al.
ESMO Open (2024) Vol. 9, Iss. 12, pp. 103987-103987
Closed Access | Times Cited: 3
Sara M. Tolaney, Nadine Tung, Antonio C. Wolff, et al.
ESMO Open (2024) Vol. 9, Iss. 12, pp. 103987-103987
Closed Access | Times Cited: 3
Reimagining Deintensification for Low-Risk Breast Cancer
Chirag Shah, Megan Kruse, Zahraa Al‐Hilli
JCO Oncology Practice (2024)
Closed Access | Times Cited: 2
Chirag Shah, Megan Kruse, Zahraa Al‐Hilli
JCO Oncology Practice (2024)
Closed Access | Times Cited: 2
Advancements in Clinical Research and Emerging Therapies for Triple-Negative Breast Cancer Treatment
Lili Xu, Pengtao Xu, Jingsong Wang, et al.
European Journal of Pharmacology (2024), pp. 177202-177202
Closed Access | Times Cited: 1
Lili Xu, Pengtao Xu, Jingsong Wang, et al.
European Journal of Pharmacology (2024), pp. 177202-177202
Closed Access | Times Cited: 1
Accelerated Partial Breast Irradiation for HER2-Positive Early-Stage Breast Cancer
Diana Roth O’Brien, Lillian Boe, Giacomo Montagna, et al.
International Journal of Radiation Oncology*Biology*Physics (2023) Vol. 118, Iss. 2, pp. 468-473
Open Access | Times Cited: 2
Diana Roth O’Brien, Lillian Boe, Giacomo Montagna, et al.
International Journal of Radiation Oncology*Biology*Physics (2023) Vol. 118, Iss. 2, pp. 468-473
Open Access | Times Cited: 2
De-Escalating Treatment Strategies for Patients with Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Early-Stage Breast Cancer
Hikmat Abdel‐Razeq
Cancers (2024) Vol. 16, Iss. 20, pp. 3478-3478
Open Access
Hikmat Abdel‐Razeq
Cancers (2024) Vol. 16, Iss. 20, pp. 3478-3478
Open Access
Nodal involvement in patients with small, clinically node-negative HER2+ breast cancer after staging with FDG-PET/CT and neoadjuvant systemic therapy
Josefien P. van Olmen, Veerle Geurts, Marie-Jeanne TFD. Vrancken Peeters, et al.
The Breast (2024) Vol. 78, pp. 103822-103822
Open Access
Josefien P. van Olmen, Veerle Geurts, Marie-Jeanne TFD. Vrancken Peeters, et al.
The Breast (2024) Vol. 78, pp. 103822-103822
Open Access
